EUVIMEDEUVIMED entdecken
Crossref

Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues

Sarah Hamidi iD, Anastasios Maniakas iD, Neal S Akhave iD, Victoria E Banuchi iD, Naifa L Busaidy iD, Ramona Dadu iD, Renata Ferrarotto iD, Theresa A Guise, Marie-Claude Hofmann iD, S Mohsen Hosseini iD, Mimi I Hu iD, Priyanka C Iyer iD und 10 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Sarah Hamidi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular, Thyroid Carcinoma, Anaplastic, ras Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

With novel RAS-targeted therapies emerging, better understanding of RAS-driven differentiated (DTC) and anaplastic (ATC) thyroid cancers is warranted.

Objective

Characterize the genotypic and phenotypic landscape of RAS-driven DTC and ATC and review current and future therapeutic avenues.

Design

Retrospective chart review between January 2015 and June 2023. Median follow-up duration 8.4 years in DTC cohort and 36.4 months in ATC cohort.

Setting

Single-center study at MD Anderson Cancer Center. Patients Individuals with RAS-altered DTC or ATC identified before kinase inhibitor exposure.

Interventions

None. Main Outcome Measures Primary objective was to describe clinical and molecular characteristics. Secondary objectives included identifying prognostic factors and assessing survival outcomes with available therapies.

Results

Among 120 RAS-driven DTC and 71 RAS-driven ATC, NRAS was the most common alteration (69% of DTC, 70% of ATC), mainly at residue Q61. Brain metastases were found in 22% of patients undergoing brain imaging (19% in DTC, 25% in ATC). Median overall survival (OS) was 15.2 years in DTC, with 49% of patients receiving at least 1 line of systemic therapy, most commonly lenvatinib (66%). Median time to systemic therapy was 3.5 years from diagnosis, and median OS from therapy initiation was 6.0 years. In ATC, median OS was 7.5 months. Stage IVC [hazard ratio (HR) = 6.78)], neck surgery (HR = 0.29), and exposure to immunotherapy (HR = 0.13) were significantly associated with mortality.

Conclusion

Advanced RAS-driven follicular-derived thyroid cancers seem to exhibit an aggressive behavior, particularly in ATC, in which prognosis remains poor despite expert multidisciplinary care. Advances in RAS-targeted therapies offer hope for improved therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinoma, FollicularThyroid Carcinoma, Anaplasticras ProteinsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedPrognosisAdultAged, 80 and overFollow-Up StudiesMutationMolecular Targeted Therapy

Stichwörter der Autor:innen

immunotherapymolecular testingprecision medicinetargeted therapythyroid cancer

Substanzen

ras Proteins

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Sarah Hamidi, Anastasios Maniakas, Neal S Akhave, Victoria E Banuchi, Naifa L Busaidy, Ramona Dadu, Renata Ferrarotto, Marie-Claude Hofmann, S Mohsen Hosseini, Mimi I Hu, Priyanka C Iyer, Mena Mansour, Vicente R Marczyk, Sinchita Roy-Chowdhuri, Steven I Sherman, Mark E Zafereo, Steven G Waguespack, Maria E Cabanillas

Förderung

  • NCI NIH HHS

Zitieren

APA

Hamidi, S., Maniakas, A., Akhave, N. S., Banuchi, V. E., Busaidy, N. L., Dadu, R., Ferrarotto, R., Guise, T. A., Hofmann, M. C., Hosseini, S. M., Hu, M. I., Iyer, P. C., Mansour, M., Marczyk, V. R., Roy-Chowdhuri, S., Sherman, S. I., Sousa, L. G., Wang, J. R., Williams, M. D., …, & Cabanillas, M. E. (2026). Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf366

Vancouver

Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, et al. Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf366

BibTeX
@article{Hamidi2026,
  author = {Hamidi, Sarah and Maniakas, Anastasios and Akhave, Neal S and Banuchi, Victoria E and Busaidy, Naifa L and Dadu, Ramona and Ferrarotto, Renata and Guise, Theresa A and Hofmann, Marie-Claude and Hosseini, S Mohsen and Hu, Mimi I and Iyer, Priyanka C and Mansour, Mena and Marczyk, Vicente R and Roy-Chowdhuri, Sinchita and Sherman, Steven I and Sousa, Luana G and Wang, Jennifer R and Williams, Michelle D and Zafereo, Mark E and Waguespack, Steven G and Cabanillas, Maria E},
  title = {Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf366}
}
Kostenlos starten →